Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH

15-06-2022 | EULAR 2022 | Conference coverage | Video

BE COMPLETE and BE OPTIMAL: How might bimekizumab impact PsA clinical practice?

Philippe Carron comments on the findings from the BE COMPLETE and BE OPTIMAL studies, and discusses how bimekizumab may impact the psoriatic arthritis treatment landscape if approved by the regulatory authorities (3:19).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Related content

25-05-2022 | Bimekizumab | Feature | Article

A quick guide to the phase 3 trials of bimekizumab in spondyloarthritis

04-06-2022 | EULAR 2022 | Conference coverage | News

Bimekizumab beneficial for psoriatic arthritis in phase 3 trials

07-06-2022 | EULAR 2022 | Conference coverage | Video

The BE COMPLETE and BE OPTIMAL trials of bimekizumab in PsA

01-06-2022 | EULAR 2022 | Conference coverage | News

BE MOBILE trials support bimekizumab for the treatment of axSpA
Image Credits